Silverfin false false 31/12/2025 01/01/2025 31/12/2025 Mr C R Reynolds 01/09/2008 Mr G T Reynolds 22/06/2021 Miss L J Reynolds 12/02/2020 Mrs L A Reynolds 09/04/2013 01 June 2026 The principal activity of the Company during the financial year was medical device distribution. 04054345 2025-12-31 04054345 bus:Director1 2025-12-31 04054345 bus:Director2 2025-12-31 04054345 bus:Director3 2025-12-31 04054345 bus:Director4 2025-12-31 04054345 2024-12-31 04054345 core:CurrentFinancialInstruments 2025-12-31 04054345 core:CurrentFinancialInstruments 2024-12-31 04054345 core:ShareCapital 2025-12-31 04054345 core:ShareCapital 2024-12-31 04054345 core:RetainedEarningsAccumulatedLosses 2025-12-31 04054345 core:RetainedEarningsAccumulatedLosses 2024-12-31 04054345 core:LandBuildings 2024-12-31 04054345 core:PlantMachinery 2024-12-31 04054345 core:Vehicles 2024-12-31 04054345 core:FurnitureFittings 2024-12-31 04054345 core:LandBuildings 2025-12-31 04054345 core:PlantMachinery 2025-12-31 04054345 core:Vehicles 2025-12-31 04054345 core:FurnitureFittings 2025-12-31 04054345 core:CostValuation 2024-12-31 04054345 core:DisposalsRepaymentsInvestments 2025-12-31 04054345 core:CostValuation 2025-12-31 04054345 core:CurrentFinancialInstruments 3 2025-12-31 04054345 core:CurrentFinancialInstruments 3 2024-12-31 04054345 bus:OrdinaryShareClass1 2025-12-31 04054345 2025-01-01 2025-12-31 04054345 bus:FilletedAccounts 2025-01-01 2025-12-31 04054345 bus:SmallEntities 2025-01-01 2025-12-31 04054345 bus:AuditExemptWithAccountantsReport 2025-01-01 2025-12-31 04054345 bus:PrivateLimitedCompanyLtd 2025-01-01 2025-12-31 04054345 bus:Director1 2025-01-01 2025-12-31 04054345 bus:Director2 2025-01-01 2025-12-31 04054345 bus:Director3 2025-01-01 2025-12-31 04054345 bus:Director4 2025-01-01 2025-12-31 04054345 core:LandBuildings core:TopRangeValue 2025-01-01 2025-12-31 04054345 core:PlantMachinery core:BottomRangeValue 2025-01-01 2025-12-31 04054345 core:PlantMachinery core:TopRangeValue 2025-01-01 2025-12-31 04054345 core:Vehicles core:TopRangeValue 2025-01-01 2025-12-31 04054345 core:FurnitureFittings core:BottomRangeValue 2025-01-01 2025-12-31 04054345 core:FurnitureFittings core:TopRangeValue 2025-01-01 2025-12-31 04054345 2024-01-01 2024-12-31 04054345 core:LandBuildings 2025-01-01 2025-12-31 04054345 core:PlantMachinery 2025-01-01 2025-12-31 04054345 core:Vehicles 2025-01-01 2025-12-31 04054345 core:FurnitureFittings 2025-01-01 2025-12-31 04054345 bus:OrdinaryShareClass1 2025-01-01 2025-12-31 04054345 bus:OrdinaryShareClass1 2024-01-01 2024-12-31 iso4217:GBP xbrli:pure xbrli:shares

Company No: 04054345 (England and Wales)

# C J MEDICAL LIMITED

### Unaudited Financial Statements
For the financial year ended 31 December 2025
Pages for filing with the registrar

C J MEDICAL LIMITED

## Unaudited Financial Statements

For the financial year ended 31 December 2025

Contents

C J MEDICAL LIMITED

## BALANCE SHEET

As at 31 December 2025
C J MEDICAL LIMITED

## BALANCE SHEET (continued)

As at 31 December 2025

| Note | 2025 |  | 2024
|  | £ |  | £
Fixed assets |  |  |  |
Tangible assets | 3 | 837,566 |  | 592,578
Investments | 4 | 0 |  | 62,500
|  | 837,566 |  | 655,078
Current assets |  |  |  |
Stocks |  | 562,856 |  | 629,660
Debtors | 5 | 981,314 |  | 1,208,428
Cash at bank and in hand |  | 2,765,862 |  | 2,015,445
|  | 4,310,032 |  | 3,853,533
Creditors: amounts falling due within one year | 6 | ( 341,252) |  | ( 562,103)
Net current assets |  | 3,968,780 |  | 3,291,430
Total assets less current liabilities |  | 4,806,346 |  | 3,946,508
Provision for liabilities |  | ( 67,809) |  | ( 4,869)
Net assets |  | 4,738,537 |  | 3,941,639
Capital and reserves |  |  |  |
Called-up share capital | 7 | 103 |  | 103
Profit and loss account |  | 4,738,434 |  | 3,941,536
Total shareholders' funds |  | 4,738,537 |  | 3,941,639

For the financial year ending 31 December 2025 the Company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

- The members have not required the Company to obtain an audit of its financial statements for the financial year in accordance with section 476;
- The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements; and
- These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime and a copy of the Statement of Income and Retained Earnings has not been delivered.

The financial statements of C J Medical Limited (registered number: 04054345) were approved and authorised for issue by the Board of Directors on 01 June 2026. They were signed on its behalf by:

Mr C R Reynolds Director |

C J MEDICAL LIMITED

## NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 December 2025
C J MEDICAL LIMITED

## NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 December 2025

##### 1. Accounting policies

The principal accounting policies are summarised below. They have all been applied consistently throughout the financial year and to the preceding financial year, unless otherwise stated.

##### General information and basis of accounting

C J Medical Limited (the Company) is a private company, limited by shares, incorporated in the United Kingdom under the Companies Act 2006 and is registered in England and Wales. The address of the Company's registered office is Unit B3 Walker Business Park, Three Mile Stone, Truro, TR4 9FB, United Kingdom.
The financial statements have been prepared under the historical cost convention, modified to include the revaluation of freehold properties and to include investment properties and certain items at fair value, and in accordance with Section 1A of Financial Reporting Standard 102 (FRS 102) ‘The Financial Reporting Standard applicable in the UK and Republic of Ireland’ issued by the Financial Reporting Council and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime.
The financial statements are presented in pounds sterling which is the functional currency of the Company and rounded to the nearest £.

##### Foreign currency

Transactions in foreign currencies are recorded at the rate of exchange at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies at the Balance Sheet date are reported at the rates of exchange prevailing at that date.

##### Turnover

Turnover comprises the fair value of the consideration received or receivable for the sale of goods and provision of services in the ordinary course of the company’s activities. Turnover is shown net of value added tax, returns, rebates and discounts and after eliminating sales within the company.
The company recognises revenue when; the amount of revenue can be reliably measured; it is probable that future economic benefits will flow to the entity; and specific criteria have been met for each of the company's activities.

##### Taxation

Current tax
Current tax is provided at amounts expected to be paid (or recoverable) using the tax rates and laws that have been enacted or substantively enacted at the Balance Sheet date.
Deferred tax
Deferred tax arises as a result of including items of income and expenditure in taxation computations in periods different from those in which they are included in the Company's financial statements. Deferred tax is provided in full on timing differences which result in an obligation to pay more or less tax at a future date, at the average tax rates that are expected to apply when the timing differences reverse, based on tax rates and laws substantively enacted at the balance sheet date. Deferred tax assets and liabilities are not discounted.

##### Tangible fixed assets

Tangible fixed assets are stated at cost or valuation, net of depreciation and any provision for impairment. Depreciation is provided on all tangible fixed assets, other than investment property and freehold land, at rates calculated to write off the cost or valuation, less estimated residual value, of each asset on a straight-line basis over its expected useful life, as follows:

Land and buildings | 50 years straight line
Plant and machinery | 1 - 4 years straight line
Vehicles | 4 years straight line
Fixtures and fittings | 2 - 4 years straight line

Residual value represents the estimated amount which would currently be obtained from disposal of an asset, after deducting estimated costs of disposal, if the asset were already of the age and in the condition expected at the end of its useful life.

##### Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to sell, which is equivalent to the net realisable value. Cost is calculated using the FIFO (first-in, first-out) method.
The cost of finished goods and work in progress comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the stocks to their present location and condition. At each reporting date, stocks are assessed for impairment. If stocks are impaired, the carrying amount is reduced to its selling price less costs to complete and sell; the impairment loss is recognised immediately in profit or loss.

##### Financial instruments

Classification
The company holds the following financial instruments:
• Investments in other financial assets; and
• Short term trade and other debtors and creditors; and
• Cash and bank balances.
All financial instruments are classified as basic.
Recognition and measurement
The company has chosen to apply the recognition and measurement principles in FRS102.
Financial instruments are recognised when the company becomes party to the contractual provisions of the instrument and derecognised when in the case of assets, the contractual rights to cash flows from the assets expire or substantially all the risks and rewards of ownership are transferred to another party, or in the case of liabilities, when the company’s obligations are discharged, expire or are cancelled.
Except for bank loans, such instruments are initially measured at transaction price, including transaction costs, and are subsequently carried at the undiscounted amount of the cash or other consideration expected to be paid or received, after taking account of impairment adjustments.
Bank loans are initially measured at transaction price, including transaction costs, and are subsequently carried at amortised cost using the effective interest method.

##### Defined contribution pension obligation

A defined contribution plan is a pension plan under which fixed contributions are paid into a pension fund and the company has no legal or constructive obligation to pay further contributions even if the fund does not hold sufficient assets to pay all employees the benefits relating to employee service in the current and prior periods.
Contributions to defined contribution plans are recognised as employee benefit expense when they are due. If contribution payments exceed the contribution due for service, the excess is recognised as a prepayment.

#### 2. Employees

| 2025 |  | 2024
| Number |  | Number
Monthly average number of persons employed by the Company during the year, including directors | 20 |  | 21

#### 3. Tangible assets

| Land and buildings |  | Plant and machinery |  | Vehicles |  | Fixtures and fittings |  | Total
| £ |  | £ |  | £ |  | £ |  | £
Cost |  |  |  |  |  |  |  |  |
At 01 January 2025 | 93,017 |  | 978,500 |  | 884,096 |  | 158,890 |  | 2,114,503
Additions | 0 |  | 563,340 |  | 82,894 |  | 23,981 |  | 670,215
Disposals | 0 |  | ( 49,891) |  | 0 |  | ( 8,311) |  | ( 58,202)
At 31 December 2025 | 93,017 |  | 1,491,949 |  | 966,990 |  | 174,560 |  | 2,726,516
Accumulated depreciation |  |  |  |  |  |  |  |  |
At 01 January 2025 | 885 |  | 875,190 |  | 493,466 |  | 152,384 |  | 1,521,925
Charge for the financial year | 1,860 |  | 259,759 |  | 119,185 |  | 15,690 |  | 396,494
Disposals | 0 |  | ( 21,158) |  | 0 |  | ( 8,311) |  | ( 29,469)
At 31 December 2025 | 2,745 |  | 1,113,791 |  | 612,651 |  | 159,763 |  | 1,888,950
Net book value |  |  |  |  |  |  |  |  |
At 31 December 2025 | 90,272 |  | 378,158 |  | 354,339 |  | 14,797 |  | 837,566
At 31 December 2024 | 92,132 |  | 103,310 |  | 390,630 |  | 6,506 |  | 592,578

#### 4. Fixed asset investments

| Other investments |  | Total
| £ |  | £
Cost or valuation before impairment |  |  |
At 01 January 2025 | 62,500 |  | 62,500
Disposals | ( 62,500) |  | ( 62,500)
At 31 December 2025 | 0 |  | 0
Carrying value at 31 December 2025 | 0 |  | 0
Carrying value at 31 December 2024 | 62,500 |  | 62,500

#### 5. Debtors

| 2025 |  | 2024
| £ |  | £
Trade debtors | 843,627 |  | 1,046,130
Short term loans to associates | 108 |  | 0
Amounts owed by directors | 0 |  | 200
Prepayments | 115,514 |  | 68,970
Other debtors | 22,065 |  | 93,128
| 981,314 |  | 1,208,428

#### 6. Creditors: amounts falling due within one year

| 2025 |  | 2024
| £ |  | £
Trade creditors | 6,326 |  | 44,578
Amounts owed to directors | 20 |  | 0
Accruals | 4,840 |  | 48,676
Corporation tax | 89,418 |  | 118,644
Other taxation and social security | 116,944 |  | 250,468
Other creditors | 123,704 |  | 99,737
| 341,252 |  | 562,103

#### 7. Called-up share capital

| 2025 |  | 2024
| £ |  | £
Allotted, called-up and fully-paid |  |  |
103 Ordinary shares of £ 1.00 each | 103 |  | 103

#### 8. Financial commitments

Other financial commitments

| 2025 |  | 2024
| £ |  | £
Lease commitments | 105,000 |  | 126,000

#### 9. Related party transactions

Other related party transactions

| 2025 |  | 2024
| £ |  | £
The Haemorrhoid Centre Limited - Company under common control | (117,311) |  | 0
Global Clinical Registry - Company where director has significant influence | 108 |  | 0

At the balance sheet date there was £117,311.31 due to and £108 owed from companies under common control. The loan is unsecured, interest free and repayable on demand.
During the year, the company paid trademark fees of £96k and accountancy fees of £138,375 to a company under common control.